Robert D. Arnold "Rusty" Email & Phone Number

A broad goal of my laboratory is integrate precision-based, multiomic strategies to advance the development of alternate dosing schedules and optimal delivery systems for existing and novel therapies for cancer. Our research is focused on translating those findings from discovery and preclinical development to clinical use. Specifically, my research interests are in optimizing drug dosing schedules and developing nanomedicines and exploiting such drug carriers for the detection and treatment of primary cancers and metastatic disease. We have a specific interest in the development and combination of vascular targeting and conventional oncolytic agents to induce immediate tumor regression and/or facilitate long-term tumor dormancy. Our primary aims are to (i) determine the direct anti-tumor effect and ability of novel nanoparticulate drug carriers to limit tumor growth and metastases in vivo, (ii) gain insights into the molecular mechanisms of the antitumor/vascular effects following acute (high-dose) and chronic (low-dose, protracted - metronomic treatments), (iii) develop a mechanistic understanding of how long-circulating nanoparticulate drug carriers can be used and optimized to enhance conventional antitumor activity while mediating novel antivascular or antiangiogenic effects, (iv) examine the use of existing and novel tumor/vascular molecular targeting moieties, (v) develop mathematical expressions (PK/PD-modeling) to describe drug exposure-response relationships, and use them to predict optimal drug dosing schedules and test new hypotheses and (vi) determine the effect of tumor microenvironment and acute and chronic concomitant administration of conventional and selective tumor vascular acting agents at high and low doses for the treatment of primary and metastatic disease.Specialties: Nanoparticulate Drug Carriers, PK, PD, Drug Disposition Studies, Bioanalysis (HPLC-Fluor, UV/VIS, MS/MS)

Listed skills include Pharmacology, In Vivo, Pharmacokinetics, Drug Delivery, and 29 others.